Domain specific monoclonal anti-factor VIII antibodies generated by inclusion body-renatured factor VIII peptides

Thrombosis Research

Volumn 101, Issue 5, 2001, Pages 405-415

  Huang, Chin Chin ^a   Li, Li Tzu ^a   Shen, Ming Ching ^b   Chen, Jen Yang ^a   Lin, Shu Wha ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Factor VIII; Monoclonal antibody; Recombinant protein

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY D2; MONOCLONAL ANTIBODY E6; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ARTICLE; CELL INCLUSION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CLONING, MOLECULAR; EPITOPES; ESCHERICHIA COLI; FACTOR VIII; FEMALE; KINETICS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PLASMIDS; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN RENATURATION; RECOMBINANT PROTEINS;

EID: 0035280118     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00417-5     Document Type: Article

References (34)

1. The role of phospholipid and factor VIIIa in the activation of bovine factor X
2. Factor VIII gene and hemophilia A
3. Characterization of the human factor VIII gene
4. Expression of active human factor VIII from recombinant DNA clones
5. Structure of human factor VIII
6. Molecular cloning of a cDNA encoding human antihemophilic factor
7. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease
8. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells
9. Thrombin proteolysis of purified factor VIII procoagulant protein. Correlation of activation with generation of a specific polypeptide
10. The size of human factor VIII heterodimers and the effects produced by thrombin
11. Proteolytic processing human factor VIII. Correlation of specific cleavages of thrombin factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity
12. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII)
13. Subunit structure of thrombin-activated human factor VIIIa
14. Human factor VIIIa subunit structure. Reconstitution of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit
15. Proteolytic inactivation of human factor VIII procoagulant protein by activated protein C and its analogy with factor V
16. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage site and correlation of proteolysis with cofactor activity
17. Regulation of factor VIII expression and activity by von Willebrand factor
18. Monoclonal antibodies to factor VIII: Their application in immunoblotting for the visualization of factor VIII in therapeutic concentrates and plasma
19. A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage
20. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine
21. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage
22. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS study group
23. A 110 amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells
24. Epitope mapping of anti-factor VIII antibodies found in patients with hemophilia A
25. Synthesis and sequence-specific proteolysis of hybrid proteins in Escherichia coli
26. Expression of human factor IX and its subfragments in Escherichia coli and generation of antibodies to the subfragments
27. Hemophilia B with point mutations at glycine-48 of the first epidermal growth factor-like domain of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex
28. Monoclonal antibodies against the human factor VIII molecule neutralize anti-hemophilic factor and ristocetin cofactor activities
29. Studies on a monoclonal antibody to human factor VIII coagulant activity, with a description of a facile two-site factor VIII coagulant antigen assay
30. The production and characterization of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII
31. Specificity of monoclonal antibodies to factor VIII:C
32. The life cycle of coagulation factor VIII in view of its structure and function